Source disclosure: February 19, 2026
STELLA PHARMA CORPORATION [4888.T]
TOKYO, Feb 19 (Pulse News Wire) – Stella Pharma Corporation (4888.T) signed a drug supply contract with Tokushukai Medical Foundation's Shonan Kamakura General Hospital for a clinical study involving boron neutron capture therapy (BNCT). The study aims to evaluate the efficacy and safety of BNCT in patients with refractory malignant tumors positive for FBPA-PET.
Under the agreement, which began on February 9, 2026, and runs until December 31, 2028, Stella Pharma will provide its Borofourine (10B) medication, Steborinin intravenous bag containing 10 mg per 300 mL, for use in the research. The hospital will utilize Neutron Therapeutics' nuBeam Suite system along with the supplied medication to assess treatment outcomes after 12 weeks.
The impact on Stella Pharma’s fiscal year 2026 March quarter performance is expected to be minor. The company will promptly disclose any significant developments related to the study.
AI-translated content. 🟢 Confidence: High See terms • Original filing